Company intelligence / Profile preview

TargeGen, Inc.

San Diego, California, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Phase 2

Overview

TargeGen developed oral small molecule kinase inhibitors targeting hematological malignancies and vascular disorders. Its lead asset TG101348 (fedratinib) was a JAK2 inhibitor for myeloproliferative diseases such as myelofibrosis. The company completed Phase I/II trials for this indication before being acquired by Sanofi in mid–2010. Other pipeline assets targeted various kinases but were discontinued or pending at the time of acquisition.

Therapeutic areas: OphthalmologyHematologyPulmonologyOncology
Modalities: Small molecules (specifically kinase inhibitors)
Industry: Biotech

Drug pipeline

1 asset

TG101348

Phase 2

Indications: Myelofibrosis, Polycythemia vera, Leukemia, Lymphoma

Beyond the preview

Go deeper on TargeGen, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TargeGen, Inc..

Explore the full profile